Phase 2
N=40
Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas
Endometriosis
Bottom Line
View on ClinicalTrials.gov: NCT01791413 ↗Enrolled (actual)
40
Serious AEs
—
Results posted
Aug 2013
Primary outcome: Primary: Percentage Changes of Serum Anti-Mullerian Hormone (AMH) at 2-week and 3-month Post Operation — -56.86; -77.72; -36.69; -66.84 percentage of serum AMH change
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- depot medroxyprogesterone acetate (Drug)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Mahidol University
- Primary completion
- Mar 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Changes of Serum Anti-Mullerian Hormone (AMH) at 2-week and 3-month Post Operation |
-56.86; -77.72; -36.69; -66.84 | — |
Summary
The purpose of this study is to evaluate the ovarian reserve changes after preoperative depot medroxyprogesterone acetate (DMPA) in women with ovarian endometrioma undergoing laparoscopic cystectomy.
Eligibility Criteria
Inclusion Criteria
- Healthy women 18-40 years old
- A diagnosis of endometrioma with diameter of at least 3 cm.
- Candidates for laparoscopic cystectomy
Exclusion Criteria
- Patients' refusal to participate
- Not candidate for depot medroxyprogesterone acetate such as: cirrhosis, chronic kidney disease, venous thrombosis
- Use of estrogen-suppressive drugs in the preceding 3 months, such as:
Oral contraceptives, GnRH analogues, Progestins, Danazol
- Pathology report present no endometriosis
Data sourced from ClinicalTrials.gov (NCT01791413). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.